Copper 64-DOTA-TLX 592
Alternative Names: 64Cu-DOTA-TLX592; 64Cu-TLX-592Latest Information Update: 24 May 2024
At a glance
- Originator Telix Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Prostate cancer
Most Recent Events
- 21 May 2024 Pharmacokinetics and adverse events data from the phase I CUPID trial in Prostate cancer released by Telix Pharmaceuticals
- 29 Jan 2024 Telix Pharmaceuticals completes a phase I trial in Prostate cancer (Diagnosis) in Australia (IV) (NCT04726033)
- 04 Aug 2021 Phase-I clinical trials in Prostate cancer (Diagnosis) in Australia (IV) (NCT04726033)